Literature DB >> 22796939

L1CAM: a major driver for tumor cell invasion and motility.

Helena Kiefel1, Sandra Bondong, John Hazin, Johannes Ridinger, Uwe Schirmer, Svenja Riedle, Peter Altevogt.   

Abstract

The L1 cell adhesion molecule (L1CAM) plays a major role in the development of the nervous system and in the malignancy of human tumors. In terms of biological function, L1CAM comes along in two different flavors: (1) a static function as a cell adhesion molecule that acts as a glue between cells; (2) a motility promoting function that drives cell migration during neural development and supports metastasis of human cancers. Important factors that contribute to the switch in the functional mode of L1CAM are: (1) the cleavage from the cell surface by membrane proximal proteolysis and (2) the ability to change binding partners and engage in L1CAM-integrin binding. Recent studies have shown that the cleavage of L1CAM by metalloproteinases and the binding of L1CAM to integrins via its RGD-motif in the sixth Ig-domain activate signaling pathways distinct from the ones elicited by homophilic binding. Here we highlight important features of L1CAM proteolysis and the signaling of L1CAM via integrin engagement. The novel insights into L1CAM downstream signaling and its regulation during tumor progression and epithelial-mesenchymal transition (EMT) will lead to a better understanding of the dualistic role of L1CAM as a cell adhesion and/or motility promoting cell surface molecule.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796939      PMCID: PMC3478260          DOI: 10.4161/cam.20832

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  108 in total

1.  Integrin and neurocan binding to L1 involves distinct Ig domains.

Authors:  M Oleszewski; S Beer; S Katich; C Geiger; Y Zeller; U Rauch; P Altevogt
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

2.  ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles.

Authors:  Paul Gutwein; Sabine Mechtersheimer; Svenja Riedle; Alexander Stoeck; Daniela Gast; Safwan Joumaa; Hanswalter Zentgraf; Mina Fogel; D Peter Altevogt
Journal:  FASEB J       Date:  2002-12-03       Impact factor: 5.191

3.  L1 mono- and polyclonal antibodies modify cell migration in early postnatal mouse cerebellum.

Authors:  J Lindner; F G Rathjen; M Schachner
Journal:  Nature       Date:  1983 Sep 29-Oct 5       Impact factor: 49.962

Review 4.  L1CAM malfunction in the nervous system and human carcinomas.

Authors:  Michael K E Schäfer; Peter Altevogt
Journal:  Cell Mol Life Sci       Date:  2010-03-17       Impact factor: 9.261

5.  Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-β1 (TGF-β)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells.

Authors:  Claudia Geismann; Alexander Arlt; Iris Bauer; Marco Pfeifer; Uwe Schirmer; Peter Altevogt; Susanne Sebens Müerköster; Heiner Schäfer
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

6.  Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.

Authors:  S Sebens Müerköster; V Werbing; B Sipos; M A Debus; M Witt; M Grossmann; D Leisner; J Kötteritzsch; H Kappes; G Klöppel; P Altevogt; U R Fölsch; H Schäfer
Journal:  Oncogene       Date:  2006-11-06       Impact factor: 9.867

7.  Close homolog of L1 is an enhancer of integrin-mediated cell migration.

Authors:  Mona Buhusi; Bentley R Midkiff; Amanda M Gates; Melanie Richter; Melitta Schachner; Patricia F Maness
Journal:  J Biol Chem       Date:  2003-04-29       Impact factor: 5.157

Review 8.  Chronic activation of ERK and neurodegenerative diseases.

Authors:  Luca Colucci-D'Amato; Carla Perrone-Capano; Umberto di Porzio
Journal:  Bioessays       Date:  2003-11       Impact factor: 4.345

9.  Neurite outgrowth patterns in cerebellar microexplant cultures are affected by antibodies to the cell surface glycoprotein L1.

Authors:  G Fischer; V Künemund; M Schachner
Journal:  J Neurosci       Date:  1986-02       Impact factor: 6.167

10.  Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion.

Authors:  F G Rathjen; M Schachner
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

View more
  75 in total

1.  βIII-Tubulin Regulates Breast Cancer Metastases to the Brain.

Authors:  Deepak Kanojia; Ramin A Morshed; Lingjiao Zhang; Jason M Miska; Jian Qiao; Julius W Kim; Peter Pytel; Irina V Balyasnikova; Maciej S Lesniak; Atique U Ahmed
Journal:  Mol Cancer Ther       Date:  2015-02-27       Impact factor: 6.261

2.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

3.  L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.

Authors:  Mac Versluis; A Plat; M de Bruyn; X Matias-Guiu; J Trovic; C Krakstad; H W Nijman; T Bosse; G H de Bock; H Hollema
Journal:  Virchows Arch       Date:  2018-08-23       Impact factor: 4.064

4.  Circulating levels of autoantibodies against L1-cell adhesion molecule as a potential diagnostic biomarker in esophageal squamous cell carcinoma.

Authors:  Y-W Xu; Y-H Peng; L-Q Ran; T-T Zhai; H-P Guo; S-Q Qiu; H-L Chen; Z-Y Wu; E-M Li; J-J Xie
Journal:  Clin Transl Oncol       Date:  2017-02-08       Impact factor: 3.405

5.  CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease.

Authors:  Min Shi; Andrej Kovac; Ane Korff; Travis J Cook; Carmen Ginghina; Kristin M Bullock; Li Yang; Tessandra Stewart; Danfeng Zheng; Patrick Aro; Anzari Atik; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; Thomas J Montine; William A Banks; Jing Zhang
Journal:  Alzheimers Dement       Date:  2016-05-24       Impact factor: 21.566

6.  Identification of diverse target RNAs that are functionally regulated by human Pumilio proteins.

Authors:  Jennifer A Bohn; Jamie L Van Etten; Trista L Schagat; Brittany M Bowman; Richard C McEachin; Peter L Freddolino; Aaron C Goldstrohm
Journal:  Nucleic Acids Res       Date:  2018-01-09       Impact factor: 16.971

7.  L1CAM: amending the "low-risk" category in endometrial carcinoma.

Authors:  Felix Kommoss; Friedrich Kommoss; Friederike Grevenkamp; Anne-Kathrin Bunz; Florin-Andrei Taran; Falko Fend; Sara Y Brucker; Diethelm Wallwiener; Birgitt Schönfisch; Karen Greif; Sigurd Lax; Annette Staebler; Stefan Kommoss
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-30       Impact factor: 4.553

8.  Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease.

Authors:  Min Shi; Changqin Liu; Travis J Cook; Kristin M Bullock; Yanchun Zhao; Carmen Ginghina; Yanfei Li; Patrick Aro; Romel Dator; Chunmei He; Michael J Hipp; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; William A Banks; Jing Zhang
Journal:  Acta Neuropathol       Date:  2014-07-06       Impact factor: 17.088

Review 9.  Extracellular vesicles shed by glioma cells: pathogenic role and clinical value.

Authors:  Dimitry A Chistiakov; Vladimir P Chekhonin
Journal:  Tumour Biol       Date:  2014-06-27

10.  Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Authors:  Inge C Van Gool; Ellen Stelloo; Remi A Nout; Hans W Nijman; Richard J Edmondson; David N Church; Helen J MacKay; Alexandra Leary; Melanie E Powell; Linda Mileshkin; Carien L Creutzberg; Vincent T H B M Smit; Tjalling Bosse
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.